Artal Group’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Artal Group’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-200,000	Closed	-$1.43M	–	142
2020 Q1	$1.43M	Buy	+200,000	New	+$2.5M	0.06%	99
2018 Q2	–	Sell	-100,000	Closed	-$3.27M	–	123
2018 Q1	$3.27M	Sell	100,000 -50,000	-33%	-$2.19M	0.04%	86
2017 Q4	$7.3M	Buy	+150,000	New	+$7.59M	0.11%	57

Other funds holding PTLA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Artal Group's PTLA Position: Q2 2020 in Review

Artal Group sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2020, closing a stake of 200,000 shares — an estimated $1.43M sold.

Artal Group first reported a position in PTLA in Q4 2017 and held it in 3 quarters. The position peaked at $7.3M in Q4 2017. 162 funds tracked by Wall St. Rank hold PTLA as of Q2 2020.

Artal Group reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
Artal Group sold 200,000 Portola Pharmaceuticals, Inc. shares in Q2 2020, an estimated $1.43M.
Artal Group first reported a position in Portola Pharmaceuticals, Inc. in Q4 2017 and held it in 3 quarters.
Artal Group's Portola Pharmaceuticals, Inc. position peaked at $7.3M in Q4 2017.
162 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2020.

Based on Artal Group's 13F filing for Q2 2020, filed 14 Aug 2020.